News
order by visits date title

10th ED. CF@BO 2019

ABOUT THE CONVENTION The investigation and optimization of crystal forms are at the forefront of industrial as well as fundamental research. The event will bring together academic and industrial experts interested in sharing experience and discussing perspectives and new challenges regarding: Recent advances in solid forms discovery Synthesis and properties of crystal forms Multicomponent crystal forms Intellectual property issues En route to the 10th Bologna’s convention on crystal for

Read all

CF@BO 2019, June 9 - 11

ABOUT THE CONVENTION The investigation and optimization of crystal forms are at the forefront of industrial as well as fundamental research. The event will bring together academic and industrial experts interested in sharing experience and discussing perspectives and new challenges regarding: Recent advances in solid forms discovery Synthesis and properties of crystal forms Multicomponent crystal forms Intellectual property issues En route to the 10th Bologna’s convention on crystal forms The meet

Read all

Controlled Substances Studies & Analysis

PolyCrystalLine received the authorization N°101/2017 from the Italian Ministry of Healthfor the study and chemical/physical analysis of controlled substances. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.

Read all

Des-Methyl-Venlafaxine Salt

  New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before any other generic desvenlafaxine products enter the market. Pristiq sales are projected to exceed one billion dollars yearly. Pristiq was approved in 2008 by Wyeth Pharmaceuticals for the treatment of major depres

Read all

FDA - GMP

PolyCrystalLine SpA has been inspected by FDA and received the GMP certification from AIFA for the physico-chemical analyses. For any request please contact us soon.

Read all

FRENCH CERTIFICATION

  PolyCrystalLine s.r.l. received the approval from French Health Ministry as a CRO for R&D activities, the French companies who use our services can benefit of a tax credit in compliance with the article 244 quater B of the French general code of taxes. (see the PDF attached)  

Read all

GMP CERTIFICATION

  PolyCrystalLine received the audit from the Health Agency for the cGMP certification. The authorization is granted on chemical/physics analyses for qualitative and quantitative determination of active ingredients, intermediates and finished products   

Read all

Highly Potent API

Polycrystalline is expanding its HPAPI offerings, up to OEB 5 level of containment for the synthesis, study and development of anti-cancer and cytotoxic APIs. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.

Read all

Pagina 1 di 3
© Copyright Polycrystalline SpA - All rights reserved - VAT IT02600021204 / powered by DibiWeb